Investors - Management Team
Arrayit Corporation is managed by a team of experienced life sciences professionals. Please review this information to learn more about our management team.
Rene Schena, Chief Executive Officer (CEO), Chairman of the Board and Director of Arrayit Corporation. Arrayit Corporation was formed from the Biotech Division of TeleChem International Inc., a company Ms. Schena co-founded in 1993. Arrayit has emerged as a world leader in microarray technology under Ms. Schena’s management. She received awards in 2002 and 2003 from Inc. Magazine as a top 500 fastest-growing, privately-held company, and in 2005 was recognized by the Silicon Valley Business Journal as the 11th largest woman-owned business in Silicon Valley. Ms. Schena’s strong business background and management expertise are key contributions to Arrayit’s infrastructure.
Ms. Schena holds a degree in Language Studies from the University of California, Santa Cruz. She has 25 years experience in international business, including translation, contract documentation and commodities trading. She worked in commodities trading with a subsidiary of ConAgra (1985-1988) and as a chemical import and distribution specialist, department manager, and later President of NuSource Chemical Corporation (1988-1993). Ms. Schena co-founded TeleChem International, Inc., continued the import and export chemical distribution specialty, expanded into government-bid business, and expanded again into the biotech sector in 1996. Her management skills, long-term contacts in the chemical industry, strong business background and knowledge of supply-chain distribution were key contributions to TeleChem and the growth of the microarray business and Arrayit. Ms. Schena manages all corporate financial, tax, legal, regulatory and human resources activities, including budgeting, tax-related activities, investments, loans, financial strategies, major contract negotiations, patent and litigation activities, legal strategies, payroll, employee reviews, benefits, insurance, claims, inventory control, corporate administrative management, regulatory compliance, regulatory reporting and agency interface.
Mark Schena, Ph.D., President, Chief Science Officer, and Director of Arrayit Corporation. Dr. Schena earned a B.A. in Biochemistry from the University of California, Berkeley in 1984 and a Ph.D. in Biochemistry from the University of California at San Francisco in 1990. In 1995, as a postdoctoral fellow at Stanford University, he published the first paper on microarrays in the premier scientific journal, Science, introducing microarrays to the world as a new scientific technology. His work rapidly led to a new field of discovery that uses microarrays to investigate both genes and proteins in research and diagnostics. Now microarrays are used in more than 100,000 laboratories in 50 countries to explore complicated questions in biology, chemistry, agriculture and medicine. The microarray field to date has produced 550,000 scientific publications. The commercial expansion of microarray technologies has created a multi-billion dollar industry with over 200 companies that produce ancillary products and services. Acknowledged by his peers for the importance of these accomplishments, Dr. Schena was proclaimed the Father of Microarray Technology by The Scientist, a broadly read scientific journal, in 2003.
Dr. Schena has authored five foundational books on the subject of microarrays including the best selling text, “Microarray Analysis” (J. Wiley and Sons) and has published more than 30 important papers in scientific journals (see appendix I). Dr. Schena has organized symposia and course work, chaired societal meetings and promoted the expansion of microarray technology - accruing over half million travel miles to speak to audiences of PhD’s, MD’s and life science professionals. Dr. Schena holds the key microarray diagnostics patent (issued in 2005) that provides for 100,000 patients to be screened for a health condition in a single, simple laboratory test. In 2001, this discovery was featured in the NOVA television documentary “Cracking the Code of Life” where Dr. Schena introduced microarrays as a diagnostic tool for the first time. In addition to valuable intellectual property, Dr. Schena has developed products, platforms and services for Arrayit that produce multi-million dollar sales. Mark’s innovation, product development, world-respected credentials and celebrity extend the ultimate scientific credibility to the product line and to Arrayit.
Todd Martinsky, Senior Vice President and Director of Arrayit Corporation. Todd Martinsky received a BA from San Jose State University, after which he served as Director of Education and Consulting at the Codd and Date Consulting Group, whose founder was famous for creating the relational database. Mr. Martinsky co-founded TeleChem International, Inc., in 1993, heading the Arrayit biotech division in 1996. His computer science consulting experience had an impact on Arrayit as he innovatively established Arrayit as an online business early on. This web-based enterprise was one of the first of its kind in this sector and helped Arrayit expand its new microarray technology sales rapidly.
Mr. Martinsky is recognized as a leader in the microarray field. He has guided and consulted with microarray professionals since the advent of commercial microarrays. He has presented as a Keynote Speaker for key microarray workshops and scientific meetings and has served on various microarray manufacturing panels. Mr. Martinsky has been an invited guest speaker for the Centers for Disease Control (CDC), The United States Department of Agriculture (USDA), and major Universities. Serving as an advisor to the U.S. Pharmacopeia (USP), he authored a chapter for a compendium on nucleic acid test methods for which he received Doctoral-level recognition. Mr. Martinsky authored chapters on microarray manufacturing methods in five books including the new 2009 “Microarray Methods and Protocols” (CRC Press). On the web, he maintains a Microarray Blog and is a respected member of the email-based microarray Gene-Arrays List Serve. Todd Martinsky has become the “number one most-quoted Microarray Executive” through Arrayit’s educational outreach program, appearing in numerous feature articles and scientific publications. He has led the Arrayit Division since 1996, bringing it to play a significant role in the industry. Mr. Martinsky has established successful business alliances that continue today. His day-to-day activities ensure that Arrayit’s patented printing technology and supporting products are applied in the field with optimal scientific and technological accuracy. Todd has played a key role in product development at Arrayit.
William Sklar, Financial Advisor of Arrayit Corporation. Mr. William L. Sklar, also known as Bill, has been Chief Financial Officer of Arrayit Corporation. Mr. Sklar served as the Chief Financial Officer of Arrayit Corporation until April 10, 2012. Mr. Sklar served as President and Consultant of Willmar Management Corp. Mr. Sklar has been a Consultant of Secure Electrans Ltd. since 1999. He served as Chief Financial Officer of The Mint Leasing, Inc. from November 18, 2008 to Mach 1, 2009. He has 20 years experience in important additional capacities including Former Director, Chairman of Audit Committee, Chairman of Compensation Committee and Member of Governance & Nominating Committee of United Health Products, Inc., former Chairman, Interim Chief Executive Officer, Interim President, Interim Chief Financial Officer, Secretary and Treasurer of PaperFree Medical Solutions Inc., former Chief Executive Officer, President, Chief Financial Officer and Chief Accounting Officer and Director of Link Media Publishing Ltd., former Director of Pathogenics, Inc., Director of Radiate Research Inc. and former President, Secretary and Director of Integrated Media Holdings, Inc. Mr. Sklar holds a Bachelor's Degree from the University of Toronto.
Forward Looking Statements
Some information contained in or incorporated by reference into this website are “forward looking statements” within the meaning of the United States private securities litigation reform act of 1995. All forward-looking statements involve risks and uncertainties. In particular, any statements regarding pro-forma finances, future sales, results of operations, operating efficiencies and product expansion are subject to known and unknown risks, uncertainties and contingencies. Many of these risks, uncertainties and contingencies are beyond the control of the company and may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. Accordingly, you should not place undue reliance on the forward-looking statements contained in this website. These forward-looking statements speak only as of the date on which the statements were made. In evaluating forward-looking statements, you should consider these risks and uncertainties. The company does not assume any obligation to update any such forward-looking statements to reflect events or circumstances after the date of posting of this information.
Copyright 1993-2018 Arrayit Corporation. All rights reserved.